Accendra Health, Inc.

Accendra Health, Inc. (ACH) Stock Analysis

$1.210

0.000 (0.00%)At close

Loading chart…
High
1.250
Open
1.220
VWAP
1.22
Vol
678.50K
Mkt Cap
Low
1.195
Amount
826.64K
EV/EBITDA, TTM
10.25

Accendra Health, Inc., formerly Owens & Minor, Inc., is a provider of products, technology, and services for health beyond the hospital for millions of people each year. The Company connects patients, providers, and insurers, delivering solutions for people living with chronic, complex health conditions. It provides delivery of products, including disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services). The Company also provides clinical and administrative support services and related products and supplies.

AI analysis of Accendra Health, Inc. (ACH)

sell

Accendra Health Inc is not a good buy right now. The current price is $1.21, and the company has reported a significant decline in revenue, with Q2 revenue down 10.1% year-over-year. Additionally, the RSI is at 34.576, indicating that the stock is oversold, but this does not guarantee a price rebound. The forward P/E ratio is 2.8604, which is low, but the company is facing challenges that could hinder recovery, such as a GAAP net loss of $89.1 million in Q2 2026. The main risk is the ongoing revenue decline and the uncertainty surrounding its recovery, as indicated by the downgrades from analysts.

Valuation Metrics

The current forward P/E ratio for Accendra Health, Inc. (ACH) is 2.86, compared to its 5-year average forward P/E of 2.99.

Forward P/E

Fair
5Y Average P/E
2.99
Current P/E
2.86
Overvalued
3.22
Undervalued
2.76

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
11.02
Current EV/EBITDA
10.25
Overvalued
14.03
Undervalued
8.02

Forward P/S

Strongly Undervalued
5Y Average P/S
0.08
Current P/S
0.04
Overvalued
0.10
Undervalued
0.06

Whales holding ACH

C

Coliseum Capital Management, LLC

+ HoldingACH

-20.52%

3M Return

Events Timeline

2026-08-10 (ET)

17:00:00

Stocks Open Lower as Middle East Uncertainty Grows

12:30:00

Major Averages Mixed at Open Amid Middle East Uncertainty

07:00:00

2026 Revenue Consensus at $2.57B, Adjusted EBITDA View Lowered to $300M-$320M

07:00:00

Accendra Health Adopts Section 382 Rights Agreement to Protect Shareholder Value

07:00:00

Accendra Health CEO Edward Pesicka to Retire by 2026

News

ACH FAQ — answered by Alphio AI

Accendra Health, Inc., formerly Owens & Minor, Inc., is a provider of products, technology, and services for health beyond the hospital for millions of people each year. The Company connects patients, providers, and insurers, delivering solutions for people living with chronic, complex health conditions. It provides delivery of products, including disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services). The Company also provides clinical and administrative support services and related products and supplies. It operates in the Healthcare sector.

Accendra Health Inc is not a good buy right now. The current price is $1.21, and the company has reported a significant decline in revenue, with Q2 revenue down 10.1% year-over-year. Additionally, the RSI is at 34.576, indicating that the stock is oversold, but this does not guarantee a price rebound. The forward P/E ratio is 2.8604, which is low, but the company is facing challenges that could hinder recovery, such as a GAAP net loss of $89.1 million in Q2 2026. The main risk is the ongoing revenue decline and the uncertainty surrounding its recovery, as indicated by the downgrades from analysts.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis